Hervolution pitch at Novo BII demo-day by Peter J. Holst

24 Jun 2019
By Hervolution

Hervolution treats cancer by target tumor virus within the human genome. In this video you can learn more about the company, where Hervolution is presented by Associate Professor Peter Johannes Holst.

Related news

News

Former F-star CEO joins Hervolution as strategic advisor

17 Feb 2020

By Hervolution

News

Hervolution attracts profile from NIH: Emeline Ragonnaud reunites with Peter J. Holst after 3 years

19 Jun 2020

By Hervolution

News

SIRION Biotech Licenses Adenovirus Technology to Danish Startup, Hervolution for its Novel Immunotherapy Design Targeting Endogenous Retrovirus (ERV)

05 Feb 2020

By Hervolution

News

Hervolution announces EUR 6M Seed financing with the participation of the European Innovation Council Fund to develop first-in-class cancer immunotherapy

24 May 2023

By Hervolution